Cytokinetics Inc

This management proposal asks stockholders to approve an amendment and restatement of the Company’s Amended and Restated 2015 Employee Stock Purchase Plan to increase the authorized share reserve by 1,000,000 shares (taking the plan reserve from 1,459,879 to 2,459,879). Management and the Board are seeking shareholder approval to ensure the plan has sufficient shares to continue offering an ESPP, which the Company views as a key employee benefit for recruiting, retaining, and motivating employees in competitive talent markets. The filing notes prior increases to the ESPP reserve (500,000 shares approved in May 2020 and 300,000 shares approved in May 2024), indicating recurring demand for additional shares as the Company grows. The Company quantifies the potential dilution impact: ESPP dilution would rise from approximately 1.2% to about 2.0% if the amendment is approved, and the Board and Compensation Committee explicitly manage dilution when administering equity programs. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code, offers purchase periods generally of about six months with a purchase price of not less than 85% of the lower of the fair market value at the offering start or purchase date, and limits participation per IRS rules. If approved, the Company intends to register the additional shares on Form S-8 following the meeting to permit issuance. The Board’s recommendation is rooted in corporate governance and talent strategy: management presents the ESPP as an important component of total rewards that aligns employee interests with stockholders and supports commercial and R&D objectives by helping secure and retain necessary talent. Shareholders should weigh the modest dilution against the potential retention and alignment benefits, the plan mechanics (discount, eligibility, and limits), and the Company’s stated governance controls over dilution and administration.

This advisory management proposal asks stockholders to cast a non-binding vote approving the compensation of the Company’s Named Executive Officers as disclosed in the proxy materials (CD&A, tables and narrative). The Company’s Compensation Committee follows a pay-for-performance philosophy and solicits an annual say-on-pay vote as a standing policy; management contends that the compensation program balances competitive pay, retention, and alignment with stockholder interests through a mix of base salary, annual cash incentive tied to corporate and (for some officers) individual goals, and long-term equity (options and RSUs) with multi-year vesting. The Board recommends approval and will consider the vote outcome when making future compensation decisions, acknowledging the advisory nature of the vote. The proxy disclosures describe detailed 2025 corporate goals (commercial launch readiness for aficamten, pipeline and research milestones, business development and finance objectives, and organizational development) and indicate the Compensation Committee exercised discretion and set a corporate achievement level of 120% for 2025, which materially affected payout determinations. The summary also highlights compensation governance features intended to mitigate risk (independent compensation consultant, stock ownership guidelines, no option repricing, clawback policy, and double-trigger CIC acceleration). Because the vote is non-binding, the practical effect is consultative, but a substantial against vote would typically prompt board engagement with shareholders and potential adjustments to executive pay policies. Shareholders evaluating this proposal should consider the alignment between disclosed pay outcomes and realized company performance, the robustness of governance protections, and the Company’s responsiveness to prior say-on-pay results.